WO2018112219A1 - Superkine - Google Patents

Superkine Download PDF

Info

Publication number
WO2018112219A1
WO2018112219A1 PCT/US2017/066449 US2017066449W WO2018112219A1 WO 2018112219 A1 WO2018112219 A1 WO 2018112219A1 US 2017066449 W US2017066449 W US 2017066449W WO 2018112219 A1 WO2018112219 A1 WO 2018112219A1
Authority
WO
WIPO (PCT)
Prior art keywords
affinity
molecule complex
receptor
complex
portions
Prior art date
Application number
PCT/US2017/066449
Other languages
English (en)
Other versions
WO2018112219A4 (fr
Inventor
Patrick Soon-Shiong
Original Assignee
Nant Holdings Ip, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nant Holdings Ip, Llc filed Critical Nant Holdings Ip, Llc
Publication of WO2018112219A1 publication Critical patent/WO2018112219A1/fr
Publication of WO2018112219A4 publication Critical patent/WO2018112219A4/fr
Priority to US16/442,265 priority Critical patent/US11053299B2/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/31Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Definitions

  • the field of the invention is cancer therapy, especially as it relates to cancer therapy with multifunctional chimeric molecule complexes.
  • ALL acute lymphoblastic leukemia
  • induction therapy is often based on a combinations of various drugs, including vincristine, prednisone, cyclophosphamide, doxorubicin, and L- asparaginase, over about 4-6 weeks, which is followed by consolidation.
  • consolidation includes administration of multiple drugs, including cytarabine and methotrexate.
  • Maintenance therapy often includes 6-mercaptopurine, methotrexate, steroids, and vincristine (while intrathecal methotrexate may be administered throughout).
  • Some leukemia patients may require a hematopoietic stem cell transplant to fully eradicate the diseased cells.
  • high-dose chemotherapy with or without radiation, is first used to ablate the patient's bone marrow. Then bone marrow stem cells from an
  • transplanted stem cells then grow and repopulate the bone marrow and blood with healthy cells.
  • transplanted stem cells grow and repopulate the bone marrow and blood with healthy cells.
  • ALL acute lymphoblastic leukemia
  • CAR-T cell therapy targeting CD 19 has shown remarkable efficacy in some patients, however, antigen escape of other malignant cells have not afforded complete and durable remission.
  • single chain bi-specific scfVs were employed in a CAR for adoptive T cell transfer (see e.g., Cancer Immunol Res. 2016 June; 4(6): 498-508).
  • modified T cells are often very difficult to prepare in therapeutic quantities.
  • the bi-specific CAR may elicit an immune response and as such not achieve full therapeutic effect.
  • certain chimeric molecules have been prepared in which two scFv portions were fused to provide a bi-specific therapeutic agent.
  • one bispecific therapeutic agent had single-chain variable fragments (scFv) against CD 16 on NK cells and against EpCAM on tumor cells to so facilitate ADCC (antigen- specific antibody dependent cell-mediated cytotoxicity.
  • the two scFv portions were coupled together via an IL15 portion to form a multi-component chimeric protein (TriKE, tri-specific killer engager; see e.g., Molecular Therapy Vol. 24 No. 7 Jul. 2016, 1312-1322; Human Vaccines & Immunotherapeutics 2016, vol. 12, No. 11, 2790- 2796; Blood 2016 128:4291).
  • Other treatments used a multimeric IL-15 based molecule that included a CD3 binding domain as is described in WO 2017/205726.
  • T cells healthy cells
  • CD3 tumor necrosis factor 3
  • immature B cells express among other markers CD 19 and CD20, and will therefore also be attacked by T cells where the therapeutic agent comprises an anti-CD3 and an anti-CD 19 portion.
  • ALL cell populations are also often genetically heterogeneous and will include cells that do not express CD19, or CD20.
  • compositions and methods in which multifunctional chimeric molecule complexes are used for the treatment of acute lymphoblastic leukemia.
  • contemplated multifunctional chimeric molecule complexes will stimulate an immune response to cancerous cells via an IL15/IL15Ra portion (e.g., via NK cell cytotoxicity and complement dependent cytotoxicity) and target a diverse population of ALL cells via more than one marker of diseased cells.
  • the compositions and methods will not target CD3 and as such will not trigger off-target cytotoxicity.
  • the chimeric molecule complex includes a first fusion protein comprising an Fc portion, an IL15 receptor portion, and a first affinity portion, wherein the first affinity portion specifically binds to one of CD 19, CD20, and CD22.
  • Contemplated chimeric molecule complexes will further include a second fusion protein comprising an IL15 portion and a second affinity portion, wherein the second affinity portion specifically binds to one of CD 19, CD20, and CD22.
  • the first and second fusion proteins form a complex via the IL15 portion and the IL15 receptor portion.
  • preferred molecule complexes include first and second affinity portions that bind different ones of CD 19, CD20, and CD22, and/or at least one of the first affinity portion and the second affinity portion comprise an scFv.
  • Particularly preferred IL15 portion comprise an IL15 N72D mutant and preferred IL15 receptor portions comprise IL15Ra.
  • fusion proteins may advantageously be prepared as recombinant polypetides in which a single polypeptide chain includes all portions, it is also contemplated that the IL15 receptor portion and the first affinity portion and/or the IL15 portion and the second affinity portion are coupled to each other via a binding portion (e.g., at least a portion of biotin, Protein A, Protein B, and/or an RNA fragment).
  • At least one of the first and second fusion proteins may also comprise an affinity portion that binds to CD3.
  • the Fc portion of the first fusion protein will comprise at least a portion of an IgG, IgM, IgA, IgD, and/or IgE antibody.
  • contemplated molecule complexes will form at least a dimer with at least a second chimeric molecule complex.
  • the second chimeric molecule complex will comprise a third fusion protein comprising an Fc portion, an IL15 receptor portion, and a third affinity portion, wherein the third affinity portion specifically binds to one of CD19, CD20, and CD22; and a fourth fusion protein comprising an IL15 portion and a fourth affinity portion, wherein the fourth affinity portion specifically binds to one of CD 19, CD20, and CD22.
  • the third and fourth fusion proteins form a complex via the IL15 portion and the IL15 receptor portion.
  • the third and the fourth affinity portions bind different ones of CD 19, CD20, and CD22.
  • at least one of the third and the fourth affinity portions bind to different ones of CD 19, CD20, and CD22 with respect to the first and the second affinity portions.
  • one of the first, second, third, and fourth affinity portions may also bind to CD3 instead of to one of CD 19, CD20, and CD22.
  • At least one of the first, second, third, and fourth affinity portion comprise an scFv, and the IL15 receptor portion and the first affinity portion and/or the IL15 portion and the second affinity portion form a single polypeptide. Additionally, in at least some aspects of the inventive subject matter, at least one Fc portion of the first and third fusion protein is coupled to an albumin. In still further contemplated aspects, at least one of the affinity portions may also be a BiKE or TriKE.
  • At least one of the affinity portions comprises a scFv portion with CDR regions grafted from or otherwise obtained from a therapeutic antibody against one of CD 19, CD20, and CD22
  • typical therapeutic antibody examples include blinatumomab, denintuzumab, rituximab, taplitumomab, afutuzumab, ofatumumab, obinutuzumab, lymphomun, ibritumomab, ocrelizumab, ocaratuzumab, ublituximab, veltuzumab, bectumomab, epratuzumab, inotuzumab, moxetumomab, and pinatuzumab.
  • the inventor also contemplates recombinant nucleic acids comprising a sequence segment encoding at least one of the first and second fusion proteins contemplated herein, as well as recombinant cells that comprising such recombinant nucleic (as extrachromosomal units or integrated in to the genome of the host cell).
  • Still further contemplated aspects include pharmaceutical compositions for treatment of acute lymphocytic leukemia that will comprise a pharmaceutically acceptable carrier in combination with a chimeric molecule complex as presented herein.
  • contemplated chimeric molecule complexes to treat acute lymphocytic leukemia is also contemplated.
  • the inventor contemplates a method of treating acute lymphocytic leukemia that comprises a step of administering a chimeric molecule complex as contemplated herein to a patient in need thereof under a protocol effective to reduce leukemia cells in the patient.
  • Fig. 1 illustrates an exemplary chimeric molecule complex.
  • Fig. 2 illustrates an exemplary dimer formed of two chimeric molecule complexes.
  • the inventive subject matter is directed to compositions and methods that provide, in the context of treatment of acute lymphoblastic leukemia, a chimeric molecule complex with multiple desirable functions for (1) targeting cancer cells, (2) activating an immune response; and (3) enabling persistence of the chimeric molecule complex to ensure the proper response.
  • ALL cells can be selectively targeted and eliminated with no off-target specificity, for example, towards immature T cells expressing CD3. Cytotoxic effect is nevertheless maintained by inclusion of an IL15/IL15 receptor portion that activates NK cells and by inclusion of an Fc portion of an antibody that helps direct complement dependent cytotoxicity towards ALL cells.
  • FIG 1 schematically illustrates one exemplary embodiment of a chimeric molecule complex 100.
  • Chimeric molecule complex 100 comprises first fusion protein 110 and second fusion protein 160.
  • the first fusion protein 110 has Fc portion 120, IL15 receptor portion 130, and a first affinity portion 140.
  • the IL15 receptor portion is preferably an IL15 receptor alpha chain.
  • First affinity portion 140 is coupled to IL15 receptor portion 130 via first linker 135.
  • Second fusion protein 160 has IL15 portion 170 coupled to second affinity portion 180 via second linker 175.
  • IL15 portion also expressly includes its mutant forms, and particularly IL15N72D.
  • the IL15 portion may be a native (typically human) IL15 or an IL15 superagonist.
  • first and second fusion proteins 110 and 160 form a complex via non-covalent but specific binding of the IL15 portion 170 to the IL15 receptor portion 130.
  • chimeric molecule complexes can be combined in dimers (or higher multimers, depending on the type of Fc portion selected), which can increase not only the effectiveness but also the number of functions of treatment. It should also be noted that such dimers need not necessarily comprise identical chimeric molecule complexes, but may indeed comprise distinct chimeric molecule complexes that so allow additional targeting (e.g., the first chimeric molecule complex targets CD 19 and CD20, while the second chimeric molecule complex targets CD22 and CD20).
  • FIG. 2 schematically and exemplarily illustrates one embodiment of a dimer 200 formed of first chimeric molecule complex 210 and second chimeric molecule complex 260.
  • First chimeric molecule complex 210 comprises first fusion protein 212 and second fusion protein 232.
  • the first fusion protein has an Fc portion 215, IL15 receptor portion 220, and a first affinity portion 230.
  • the IL15 receptor portion is preferably a (human) IL15 receptor alpha chain.
  • First affinity portion 230 is coupled to IL15 receptor portion 220 via first linker 225.
  • Second fusion protein 232 has a (human) IL15 portion 235 coupled to second affinity portion 245 via second linker 240.
  • second chimeric molecule complex 260 comprises third fusion protein 262 and fourth fusion protein 282.
  • the third fusion protein has Fc portion 265, IL15 receptor portion 270, and a third affinity portion 280, coupled to IL15 receptor portion 270 via third linker 275.
  • the IL15 receptor portion is preferably a (human) IL15 receptor alpha chain.
  • Fourth fusion protein 282 has a (human) IL15 portion 285 coupled to fourth affinity portion 295 via fourth linker 290.
  • a fifth affinity portion 267 may be coupled to the Fc portion 265 of the third fusion protein 262 via fifth linker 266.
  • the fifth affinity portion may also be coupled to the Fc portion 215 or to any one of first through fourth affinity portions, not illustrated.
  • the first chimeric molecule complex 210 and the second chimeric molecule complex 260 are bound together via disulfide bond 250 (and hydrophobic interactions between Fc portions).
  • dimer 200 is a heterodimer, where first chimeric molecule complex 210 and second chimeric molecule complex 260 are different, most typically by virtue of different affinity portions. Therefore, multiple advantageous functions can be combined in one dimer.
  • chimeric molecule complex 100 contains affinity portions, such as first affinity portion 140 and second affinity portion 180, which will preferably bind with cancer- specific antigens.
  • the diseased cells present surface proteins CD 19, CD20, and CD22.
  • CD 19, CD20, and CD22 surface proteins
  • therapies targeting only one of the surface markers will likely not eradicate cancer cells lacking that surface marker.
  • first affinity portion 140 and/or second affinity portion 180 will have an affinity toward at least a portion of one or more, and most typically at least two or more of CD 19, CD20, and CD22.
  • one of the affinity portions may also have affinity towards CD3, a T cell specific marker to so attract and bind a cytotoxic T cell to the ALL B cell.
  • first affinity portion 140 comprises an antibody fragment, most typically a scFv, which binds to the target molecule.
  • first affinity portion 140 and/or second affinity portion 180 may also comprise an aptamer, a protein identified by phage or mRNA display, or other CD 19, CD20, CD22, or CD3, or specific ligands that target and bind to CD 19, CD20, CD22, or CD3, respectively.
  • first affinity portion 140 may have an affinity to a molecule distinct from the affinity of second affinity portion 180. This would allow for more refined targeting of multiple targets on the ALL cells. While not wishing to limit the subject matter, it is contemplated, for example, first affinity portion 140 could have an affinity to CD 19 and second affinity portion 180 could have an affinity to CD20 or CD22 (or CD3 where T cell targeting is desired). Or, first affinity portion 140 could have an affinity to CD20 and second affinity portion 180 could have an affinity to CD 19, CD22, or CD3. Further still, first affinity portion 140 could have an affinity to CD22 and second affinity portion 180 could have an affinity to CD19, CD20, or CD3.
  • first affinity portion 140 could have an affinity to CD3 and second affinity portion 180 could have affinity to CD19, CD20, or CD22.
  • first chimeric molecule complexes may have identical affinity portions (e.g., first and second affinity portions binding CD19, or CD20, or CD22) while the second chimeric molecule complex may have identical or different affinity portions as discussed above.
  • affinity portions may have other targets besides Cluster of Differentiation (CD) molecules, such as various cancer-specific antigens or tumor neoepitopes.
  • CD Cluster of Differentiation
  • contemplated compositions need not bind to CD3 of cytotoxic T cells to so exert therapeutic effect, but will nevertheless be effective in triggering cytotoxic effects due to at least the IL15/IL15 receptor portion and/or Fc portion that activates NK cells (in proximity of the aggregated ALL cells). Moreover, and even without NK cell activation, complement dependent cytotoxic effects may be triggered by the presence of the Fc portion in the chimeric molecule complexes.
  • contemplated chimeric molecule complexes may be administered together with NK cells, and especially NK92 cells and derivatives thereof.
  • suitable NK cells may be autologous NK cells from the patient, and such autologous NK cells may be isolated from whole blood, or cultivated from precursor or stem cells using methods known in the art.
  • the NK cells need not be autologous, but may also be allogenic or heterologous NK cells.
  • the NK cells are genetically engineered to achieve one or more desirable traits, are NK92 cells, or derivatives of NK92 cells.
  • the genetically engineered NK cell is a NK92 derivative that is modified to have reduced or abolished expression of at least one killer cell immunoglobulin-like receptor (KIR), which will render such cells constitutively activated (via lack of/reduced inhibition).
  • KIR killer cell immunoglobulin-like receptor
  • NK92 cells exhibit an unusual receptor expression profile, expressing a relatively large number of activating (e.g., NKp30, NKp46, 2B4, NKGD, CD28) receptors. Conversely, NK92 cells also express few inhibitory receptors (e.g., NKGA/B, low levels of KIR2DL4, ILT-2), and lack most of the killer inhibitory receptors (KIRs) clonally expressed on normal NK cells.
  • activating e.g., NKp30, NKp46, 2B4, NKGD, CD28
  • NK92 cells also express few inhibitory receptors (e.g., NKGA/B, low levels of KIR2DL4, ILT-2), and lack most of the killer inhibitory receptors (KIRs) clonally expressed on normal NK cells.
  • KIRs killer inhibitory receptors
  • NK92 expresses relatively high levels of molecules involved in the perforin-granzyme cytolytic pathway as well as additional cytotoxic effector molecules including tumor necrosis factor (TNF)-superfamily members FasL, TRAIL, TWEAK, TNF- alpha, indicating the ability to kill via alternative mechanisms.
  • TNF tumor necrosis factor
  • NK92 cells also express other molecules implicated immune effector cell regulation (CD80, CD86, CD40L, TRANCE) whose relevance in NK killing is unclear.
  • suitable NK cells may have one or more modified KIR that are mutated such as to reduce or abolish interaction with MHC class I molecules.
  • one or more KIRs may also be deleted or expression may be suppressed (e.g., via miRNA, siRNA, etc.).
  • Most typically, more than one KIR will be mutated, deleted, or silenced, and especially contemplated KIR include those with two or three domains, with short or long cytoplasmic tail.
  • modified, silenced, or deleted KIRs will include KIR2DL1, KIR2DL2, KIR2DL3, KIR2DL4, KIR2DL5A, KIR2DL5B, KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS4, KIR2DS5, KIR3DL1, KIR3DL2, KIR3DL3, and KIR3DS1.
  • modified cells may be prepared using protocols well known in the art. Alternatively, such cells may also be commercially obtained from NantKwest (see URL www.nantkwest.com) as aNK cells ('activated natural killer cells).
  • the genetically engineered NK cell may also be an NK92 derivative that is modified to express the high-affinity Fey receptor (CD16).
  • CD16 high-affinity Fey receptor
  • Sequences for high-affinity variants of the Fey receptor are well known in the art (see e.g., Blood 2009 113:3716-3725), and all manners of generating and expression are deemed suitable for use herein. Expression of such receptor is believed to allow specific targeting of tumor cells using antibodies that are specific to a patient's tumor cells (e.g., neoepitopes), a particular tumor type (e.g., her2neu, PSA, PSMA, etc.), or that are associated with cancer (e.g., CEA-CAM).
  • such antibodies are commercially available and can be used in conjunction with the cells (e.g., bound to the Fey receptor).
  • such cells may also be commercially obtained from NantKwest as haNK cells ('high- affinity natural killer cells).
  • the genetically engineered NK cell may also be genetically engineered to express a chimeric T-cell receptor.
  • the chimeric T-cell receptor will have a scFv portion or other ectodomain with binding specificity against a tumor associated antigen, a tumor specific antigen, and a cancer neoepitope.
  • an NK cell may also be commercially obtained from NantKwest as taNK cells ('target-activated natural killer cells').
  • chimeric molecule complex 100 is the activation of an immune response to ALL. Most typically, this is achieved by providing an IL15 portion (preferably human IL15) in association with the alpha chain of the IL15 receptor (preferably human IL15Ra) as components of the chimeric molecule complex.
  • IL15 portion 170 preferably a superagonist version bound to the alpha chain of IL- 15 receptor 130. It should be appreciated that the so bound IL- 15 (as opposed to free IL15) strongly activates cells expressing the beta and gamma chain of the IL-15 receptor, which are, for example, found on cytotoxic T-cells and NK cells.
  • this chimeric molecule complex (or dimer as shown in Figure 2) will advantageously activate NK cells and T-cells, stimulate their proliferation, and even lead to memory NK/T cell formation.
  • IL15 also exerts inhibitory effect of immune suppressor cells, and particularly on Tregs and MDSCs.
  • contemplated methods as described herein will promote formation of activated and proliferating NK and cytotoxic T-cells, memory NK cells expressing NKG2C, memory T-cells, and T-cells that act like NK cells via their NKG2D properties.
  • the IL15 receptor should have a minimum length to enable specific binding of IL15 as is discussed in more detail below (e.g., have no more than 10%, 15%, or 30% loss of binding affinity compared with IL15 receptor wild type).
  • IL15 can be a native IL15 or a genetically engineered IL15 (e.g., with N72D mutation to so form a superagonist).
  • contemplated chimeric molecule complexes have significantly increased persistence (i.e., extended serum half life time), which allows the molecule to perform its functions while delaying degradation in the blood stream.
  • the Fc portion significantly increased the lifespan of IL15 in circulation as compared to IL15 per se. This provides the chimeric molecule complex with persistence, thus prolonging the activity of the molecule in circulation.
  • the Fc portion may include at least an Fc portion of an IgG, IgM, IgA, IgD, or IgE antibody.
  • first affinity portion from N-to C-terminus
  • first fusion protein may also be arraigned as follows: IL-15 receptor, Fc portion, first affinity portion.
  • second affinity portion is arranged, from N- to C-terminus as follows: second affinity portion, IL15 portion.
  • chimeric molecule complexes can be expressed from one or more nucleic acid in patient cells in vivo, in patient or mammalian production cells (e.g., CHO cells) in vitro, or where desired in other cells such as bacteria, yeast, or non-mammalian cells.
  • mammalian production cells e.g., CHO cells
  • other cells such as bacteria, yeast, or non-mammalian cells.
  • the individual components of the fusion proteins are expressed from a recombinant nucleic acid as a single polypeptide, typically with short and flexible linker sequences in between the individual components.
  • the individual components can be expressed individually and are then coupled together after expression. Such coupling will typically include use of high-affinity binding pairs such as biotin/avidin, protein A/G, short nucleic acids with sequence complementarity, etc.
  • the fusion protein (components) of the chimeric molecule complex will be co-expressed within the same cell.
  • contemplated chimeric molecule complexes can be prepared as an anti- CD19 (or anti-CD20 or anti-CD22) scFv/huIL-15N72D fusion protein in complex with (i.e., non-covalently bound to) an anti-CD20 (or anti-CD 19 or anti-CD22) scFv/huIL- 15RaSu/hulgGl Fc fusion protein, which may optionally also include an anti-CD3 affinity portion in addition to anti-CD 19/20/22 or as a replacement of one of the CD19/20/22 affinity portions.
  • the affinity portions are preferably scFv, but could also have a BiKE or TriKE configuration.
  • Suitable sequences for affinity portions may be derived from known antibodies or fragments thereof that bind CD 19, CD20, or CD22, including Fab and scFv.
  • suitable known antibodies with anti-CD19 binding include blinatumomab, SGN-CD19A, and taplitumomab paptox (anti-CD 19)
  • suitable known antibodies with anti-CD20 binding include rituximab, afutuzumab, ofatumumab, obinutuzumab, AME-133, FBTA05, ibritumomab tiuxetan, KM3065, ocrelizumab, ocaratuzumab, PR0131921, ublituximab, veltuzumab, (anti-CD20), and suitable known antibodies with anti-CD22 binding include bectumomab, epratuzumab, inotuzumab ozogamicin, mo
  • affinity portions may be directly from the above antibodies.
  • contemplated affinity portions may be prepared by CDR grafting into the scFv or other affinity portion using methods known in the art (see e.g., Methods Mol Biol. 2012;907:237-45; Monoclon Antib Immunodiagn Immunother. 2015 Dec 1 ; 34(6): 404-417; or J Biol Chem. 2010 Mar 19; 285(12): 9054-9066).
  • scFv or other binders with high specificity and affinity i.e., K D equal or less than 10 "9 M
  • K D the specificity and affinity
  • scFv or other binders with high specificity and affinity may be derived from phage display or mRNA display following known procedures (see e.g., Hum Vaccin Immunother. 2012 Dec 1 ; 8(12): 1817-1828; or Methods. 2013 Mar 15; 60(1): 10.1016).
  • IL15 refers to all known IL15 sequences (including isoforms, prepro, and pro forms), preferably mammalian, and most preferably human or humanized forms.
  • contemplated IL-15 proteins also include mutant forms, and particularly mutants with higher biological activity such as N72D mutant form (see e.g., Zhu et al., J Immunol, 183: 3598- 3607, 2009).
  • suitable IL15 sequences can be found under Genbank accession numbers X91233 (Genomic DNA), CH471056 (Genomic DNA), or X94223 (mRNA), AK290619 (mRNA), BC100961 (mRNA), and the protein sequence is known under Genbank accession numbers X91233 (Genomic DNA), CH471056 (Genomic DNA), or X94223 (mRNA), AK290619 (mRNA), BC100961 (mRNA), and the protein sequence is known under
  • IL15 receptor it is contemplated that all known IL15 receptor sequences are deemed suitable for use herein. However, especially preferred receptor sequences are high- affinity IL15R alpha chain (IL15Ra) receptors, and particularly human or humanized IL15Ra. Thus, the term "IL15 receptor” as used herein refers to all IL- 15 forms (including all isoforms), preferably mammalian, and most preferably human or humanized forms.
  • suitable IL15Ra sequences can be found under Genbank accession number AY316538 (Genomic DNA), CH471072 (Genomic DNA), or CR457064 (mRNA), AK304211 (mRNA), BC121140 mRNA, and the protein sequence is known under UniProtKB identifier Q 13261.
  • the fusion proteins may also comprise an Fc domain of an antibody.
  • Fc domains will ultimately be present as a dimer as exemplarily shown in Figure 2.
  • immunoglobulin from which the Fc domain is obtained is a mammalian, and most preferably human immunoglobulin, and especially IgGl and IgG2.
  • Other suitable Fc domains may be derived from different Ig classes (such as IgG, IgA, IgE) or subclasses (e.g., IgGl, IgG2, IgG3, IgAl, IgGA2) or variants thereof (see e.g., WO 97/34631 and WO 96/32478).
  • Fc domains are well known in the art and suitable sequences can be obtained from publically available sources such as GenBank, EMBL, SwissProt, etc.
  • a first fusion protein containing IL15Ra (or portion thereof) comprises an anti-CD20 scFv portion coupled via a linker to a hu-IL15RaSu portion coupled via a linker to a hu-lgGl Fc portion.
  • Such first fusion protein forms a complex (via IL15/IL15Ra binding) with a second fusion protein containing IL15 (or portion thereof) that comprises an anti-CD 19 scFv portion coupled via a linker (as discussed below) to a hu-IL15N72D portion.
  • Such complex may then form an antibody-like dimer via interaction and disulfide bond formation of the two Fc portions.
  • contemplated Fc fusion proteins will have an in vivo pharmacokinetic profile comparable to that of human IgG with a similar isotype, and as such substantially increase the halflife time (up to 21 days) as compared to IL15 alone.
  • IL15N72D IL-15 super-agonist
  • ALT-803 IL-15Ra Fc fusion protein
  • the super agonist complex has at least 25 -times the activity of the native cytokine in vivo (see e.g., Cytokine, 56: 804-810, 2011).
  • Such advantage is expected to persist where such or similar scaffolds are used to carry one or more affinity portions.
  • contemplated fusion proteins will preferably include a (preferably flexible) peptide linker between each of the individual components complexes.
  • suitable linker sequences will include between about 7 to 20 amino acids, and preferably between about 10 to 20 amino acids.
  • suitable linker sequences are preferably flexible to reduce steric hindrance and/or facilitate proper folding/tertiary structure.
  • linkers may include amino acids with small side chains, such as glycine, alanine and serine, to provide for flexibility (G4S linker). Where desired, such mini- sequences may be repeated to achieve a desired length.
  • linker sequences are also deemed suitable and appropriate linkers are known in the art (e.g., Whitlow, M. et al., (1991) Methods: A Companion to Methods in Enzymology, 2:97-105). Therefore, most typically a linker sequence is between the affinity portion and the IL15 or IL15Ra, and between the IL15Ra and the Fc portion.
  • contemplated fusion proteins are encoded on a recombinant nucleic acid, typically with codon usage adapted to the host cell that is used to express the fusion proteins.
  • the chimeric fusion protein complexes may be produced in vivo or in vitro. Therefore, the recombinant nucleic acid may be part of a viral nucleic acid (e.g., recombinant adenovirus that also encodes one or more neoepitopes or polytopes, optionally with co- stimulatory molecules) or part of a DNA vaccine.
  • the recombinant nucleic acid may be a RNA or DNA that is transfected into a production cell to generate recombinant protein.
  • the recombinant nucleic acid is part of a vector for extrachromosomal replication such as a phage, virus, plasmid, phagemid, cosmid, or YAC.
  • a DNA plasmid is constructed to encodes the fusion proteins contemplated herein and is used to prepare the complexes in clinically meaningful quantities.
  • the recombinant nucleic acid can be inserted into an appropriate expression vector (i.e., a vector that contains the necessary elements for the transcription and translation of the inserted protein-coding sequence).
  • a variety of host- vector systems may be utilized to express the protein-coding sequence, including mammalian cell systems infected with a virus (e.g., vaccinia virus, adenovirus, etc.), insect cell systems infected with virus (e.g., baculovirus), microorganisms such as yeast containing yeast vectors, or bacteria transformed with bacteriophage DNA, plasmid DNA or cosmid DNA.
  • a virus e.g., vaccinia virus, adenovirus, etc.
  • insect cell systems infected with virus e.g., baculovirus
  • microorganisms such as yeast containing yeast vectors, or bacteria transformed with bacteriophage DNA, plasmid DNA or cosmid DNA.
  • any one of a number of suitable transcription and translation elements may be used.
  • the fusion proteins described herein are preferably produced by standard recombinant DNA techniques.
  • compositions and methods Another advantage of contemplated compositions and methods is that the step of purification is greatly simplified because the entire chimeric molecule complex can be pulled out of solution by the binding of the Fc portion to a corresponding affinity protein. Therefore, in preferred embodiments, the Fc portion is ideally long enough to (a) facilitate the isolation of the chimeric molecule complex with any affinity protein that binds to the Fc portion (e.g. Protein A or G), and/or (b) facilitate the binding to the Sudlow II domain in albumin.
  • the chimeric molecule complex can be administered as protein complexes with albumin.
  • IL15 can be further coupled to alpha-CD3, cellulose binding protein, and/or oligohistidine for the purpose of easier affinity purification.
  • IL15 could be bound to IL2 or another cytokine portion to further enhance activation capability.
  • first and second chimeric molecule complexes can be made in separate batches as homodimers.
  • the batches can then be combined and a reducing agent can then be added to split the bonds between homodimers so the chimeric molecule complexes dissociate.
  • the reducing agent can then be pulled out (e.g. via dialysis), which will cause chimeric molecule complexes to re-associate, but this time in lst-lst, 2nd-2nd, and lst-2nd combinations.
  • Further details and methods of producing fusion proteins based on IL15/IL15Ra are described in WO 2017/205726, which is incorporated by reference herein.
  • compositions contemplated herein may be formulated according to conventional pharmaceutical practice (see, e.g., Remington: The Science and Practice of Pharmacy (20th ed.), ed. A. R. Gennaro, Lippincott Williams & Wilkins, 2000 and Encyclopedia of Pharmaceutical Technology, eds. J.
  • formulations may further include appropriate excipients that, upon administration, release the therapeutic agent in a controlled manner.
  • excipients include single or multiple unit tablet or capsule compositions, oil solutions, suspensions, emulsions, microcapsules, microspheres, molecular complexes, nanoparticles, patches, and liposomes.
  • the pharmaceutical compositions comprising a fusion protein complex of the invention may be in a form suitable for sterile injection.
  • the suitable active therapeutic(s) are dissolved or suspended in a parenterally acceptable liquid vehicle.
  • acceptable vehicles and solvents that may be employed are water, water adjusted to a suitable pH by addition of an appropriate amount of hydrochloric acid, sodium hydroxide or a suitable buffer, 1,3-butanediol, Ringer's solution, and isotonic sodium chloride solution and dextrose solution.
  • the aqueous formulation may also contain one or more preservatives (e.g., methyl, ethyl or n-propyl p-hydroxybenzoate).
  • a dissolution enhancing or solubilizing agent can be added, or the solvent may include 10-60% w/w of propylene glycol.
  • Human dosage amounts are initially determined by extrapolating from the amount of compound used in mice or non-human primates, as a skilled artisan recognizes it is routine in the art to modify the dosage for humans compared to animal models.
  • the dosage may vary from between about 1 ⁇ g compound/kg body weight to about 50 mg compound/kg body weight; or from about 5 mg/kg body weight to about 40 mg/kg body weight or from about 10 mg/kg body weight to about 30 mg/kg body weight; or from about 50 mg/kg body weight to about 20 mg/kg body weight; or from about 100 mg/kg body weight to about 10 mg/kg body weight; or from about 150 mg/kg body weight to about 500 mg/kg body weight.
  • the dose is about 0.01, 0.05, 0.1, 1, 5, 10, 25, 50, 75, 100, 150, 200,250, 300, 350,400,450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, or 1 ,000 mg/kg body weight.
  • doses are in the range of about 5 mg compound/Kg body weight to about 20 mg compound/kg body weight.
  • the doses are about 0.01, 0.05, 0.1, 1, 5, 8, 10, 12, 14, 16 or 18 mg/kg body weight.
  • chimeric molecule complexes will be administered in formulations suitable for injection in therapeutically effective amounts.
  • Therapeutically effective amounts can range from 1 ng to 1,000 mg, from 1 ⁇ g to 500 mg, from 100 ⁇ g to 100 mg.
  • Solubility co-solvents or detergents can be used to increase the storage stability.
  • mixed-phase or two-phase liquid systems can be used.
  • chimeric molecule complexes will be formulated in a liquid carrier ready to use.
  • the chimeric molecule complexes can also be formulated in a dried form for reconstitution, by lyophilization or freeze drying.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne des compositions et des procédés comprenant des complexes de molécules chimériques qui fournissent de manière avantageuse une signalisation d'activation à des cellules immunocompétentes lorsqu'elles sont liées à des cellules ALL. En outre, les complexes de molécules chimériques comprennent une partie Fc pour prolonger le temps de demi-vie du sérum et faciliter la purification.
PCT/US2017/066449 2010-09-21 2017-12-14 Superkine WO2018112219A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US16/442,265 US11053299B2 (en) 2010-09-21 2019-06-14 Superkine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662434389P 2016-12-14 2016-12-14
US62/434,389 2016-12-14

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/238,925 Continuation-In-Part US8507222B2 (en) 2010-09-21 2011-09-21 Multimeric IL-15 soluble fusion molecules and methods of making and using same
US16/442,265 Continuation-In-Part US11053299B2 (en) 2010-09-21 2019-06-14 Superkine

Publications (2)

Publication Number Publication Date
WO2018112219A1 true WO2018112219A1 (fr) 2018-06-21
WO2018112219A4 WO2018112219A4 (fr) 2018-08-02

Family

ID=62559288

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/066449 WO2018112219A1 (fr) 2010-09-21 2017-12-14 Superkine

Country Status (1)

Country Link
WO (1) WO2018112219A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022179004A1 (fr) * 2020-02-27 2022-09-01 启愈生物技术(上海)有限公司 Protéine de fusion à triple fonction de ciblage tumoral, anti-cd3 et d'activation des lymphocytes t, et son utilisation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090324538A1 (en) * 2007-05-11 2009-12-31 Altor Bioscience Corporation Fusion molecules and IL-15 variants
US20150374790A1 (en) * 2014-06-30 2015-12-31 Altor Bioscience Corporation Il-15-based molecules and methods of use thereof
US9255141B2 (en) * 2010-09-21 2016-02-09 Hing C. Wong Multimeric IL-15 soluble fusion molecules and methods of treating neoplasia and HIV using same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090324538A1 (en) * 2007-05-11 2009-12-31 Altor Bioscience Corporation Fusion molecules and IL-15 variants
US9255141B2 (en) * 2010-09-21 2016-02-09 Hing C. Wong Multimeric IL-15 soluble fusion molecules and methods of treating neoplasia and HIV using same
US20150374790A1 (en) * 2014-06-30 2015-12-31 Altor Bioscience Corporation Il-15-based molecules and methods of use thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
RAPONI, S. ET AL.: "Flow cytometric study of potential target antigens ( CD 19, CD 20, CD 22, CD 33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases", LEUKEMIA & LYMPHOMA, vol. 52, no. 6, June 2011 (2011-06-01), pages 1098 - 1107 *
SCHMOHL, J. U. ET AL.: "Enhanced ADCC and NK cell activation of an anticarcinoma bispecific antibody by genetic insertion of a modified IL -15 cross-linker", MOLECULAR THERAPY, vol. 24, no. 7, July 2016 (2016-07-01), pages 1312 - 1322, XP055509291 *
SUN, L. L. ET AL.: "Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies", SCIENCE TRANSLATIONAL MEDICINE, vol. 7, no. 287, 13 May 2015 (2015-05-13), pages 1 - 10, XP055241859 *
VALLERA, D. A. ET AL.: "IL 15 trispecific killer engagers (TriKE) make natural killer cells specific to CD 33+ targets while also inducing persistence, in vivo expansion, and enhanced function", CLINICAL CANCER RESEARCH, vol. 22, no. 14, 15 July 2016 (2016-07-15), pages 3440 - 3450, XP055509304 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022179004A1 (fr) * 2020-02-27 2022-09-01 启愈生物技术(上海)有限公司 Protéine de fusion à triple fonction de ciblage tumoral, anti-cd3 et d'activation des lymphocytes t, et son utilisation

Also Published As

Publication number Publication date
WO2018112219A4 (fr) 2018-08-02

Similar Documents

Publication Publication Date Title
US11053299B2 (en) Superkine
US20210046112A1 (en) Methods for Enhancing Efficacy of Therapeutic Immune Cells
ES2692206T3 (es) Inmunoterapia combinada de receptores de reconocimiento de antígenos y células hematopoyéticas para el tratamiento de enfermedades
US10117896B2 (en) Use of a trans-signaling approach in chimeric antigen receptors
Wu et al. B7H6-specific bispecific T cell engagers lead to tumor elimination and host antitumor immunity
JP3442265B2 (ja) 抗−腫瘍免疫誘導のための二−および三特異抗体
JP2022502037A (ja) コラーゲンに局在化される免疫調節分子およびその方法
KR20190039597A (ko) 세포 치료요법을 위한 항상성 활성 사이토킨 수용체
AU2018336791A1 (en) Compositions for chimeric antigen receptor T cell therapy and uses thereof
CA3071282A1 (fr) Lymphocytes t recepteurs d'antigenes chimeriques deficients en recepteurs de lymphocyte t et procedes d'utilisation correspondants
Junghans The challenges of solid tumor for designer CAR-T therapies: a 25-year perspective
JP7404279B2 (ja) 様々な構築物最適化を備えたt細胞抗原カプラ
US11472860B2 (en) Chimeric antigen receptors
Stern et al. CAR T cell therapy progress and challenges for solid tumors
CA3107119A1 (fr) Utilisation de l'interleukine-7 et de cellules effectrices immunitaires porteuses du recepteur antigenique chimerique (car) pour traiter une tumeur
Park et al. Expression of anti-HVEM single-chain antibody on tumor cells induces tumor-specific immunity with long-term memory
KR20210150432A (ko) 인간화 항-dll3 키메라 항원 수용체 및 이의 용도
US20210032371A1 (en) Enhanced Immunogenicity For GPI-anchored Antigens
WO2018112219A1 (fr) Superkine
KR20210151173A (ko) 인간화된 항-폴레이트 수용체 1 키메라 항원 수용체 및 그의 용도
US20230134725A1 (en) Fusion Protein Extensions
JP2022519713A (ja) Car操作されたt細胞およびサイトカインを含む治療
JP2022528422A (ja) インターロイキン2(il2)およびインターフェロン(ifn)を含む治療
WO2022092277A1 (fr) Lymphocytes t-récepteur antigénique chimérique (car) exprimant le récepteur cxcl12
Kassab et al. Immunomodulatory Methods

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17880417

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17880417

Country of ref document: EP

Kind code of ref document: A1